Redeye remains positive to Strax after a solid Q3-profitability beat. Following the report, we have minor changes to our near-term estimates while most notably increased our Q4 EBIT-estimate by +30%. We continue to believe that the market underestimates STRAX's ability to create long term value, and our base case valuation offers solid upside potential.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/